Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 650-656

  Agrawal, Manish ^a   Abraham, Jame ^b   Balis, Frank M ^a   Edgerly, Maureen ^a   Stein, Wilfred D ^c   Bates, Susan ^a   Fojo, Tito ^a   Chen, Clara C ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRANILIC ACID DERIVATIVE; CYCLOSPORIN; EPIPODOPHYLLOTOXIN; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NAVELBINE; PACLITAXEL; TARIQUIDAR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE; QUINOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME SUBSTRATE; FEMALE; HEART; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER; LUNG; MALE; METASTASIS; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR; DRUG EFFECT; DRUG RESISTANCE; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; SCINTISCANNING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUINOLINES; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; VINBLASTINE;

EID: 0037316891     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Juliano, R. L., and Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455: 152-162, 1976.
2. Fojo, A., Akiyama, S., Gottesman, M. M., and Pastan, I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res., 45: 3002-3007, 1985.
3. Beck, W. T., Mueller, T. J., and Tanzer, L. R. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res., 39: 2070-2076, 1979.
4. Mistry, P., Stewart, A. J., Dangerfield, W., Okiji, S., Liddle, C., Bootle, D., Plumb, J. A., Templeton, D., and Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res., 61: 749-758, 2001.
5. Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P., and Callaghan, R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol., 28: 403-411, 1999.
6. Piwnica-Worms, D., Chiu, M. L., Budding, M., Kronauge, J. F., Kramer, R. A., and Croop, J. M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res., 53: 977-984, 1993.
7. Rao, V. V., Chiu, M. L., Kronauge, J. F., and Piwnica-Worms, D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J. Nucl. Med., 35: 510-515, 1994.
8. Beaulieu, E., Demeule, M., Ghitescu, L., and Beliveau, R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J., 326: 539-544, 1997.
9. Sugawara, I., Akiyama, S., Scheper, R. J., and Itoyama, S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett., 112: 23-31, 1997.
10. Ferry, D. R., Traunecker, H., and Kerr, D. J. Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer, 32: 1070-1081, 1996.
11. Fisher, G. A., and Sikic, B. I. Clinical studies with modulators of multidrug resistance. Hematol. Oncol. Clin. N. Am., 9: 363-382, 1995.
12. Bradshaw, D. M., and Arceci, R. J. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol., 16: 3674-3690, 1998.
13. Fisher, G. A., Lum, B. L., Hausdorff. J., and Sikic, B. I. Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer, 32: 1082-1088, 1996.
14. Robey, R., Bakke, S., Stein, W., Meadows, B., Litman, T., Patil, S., and Bates, S. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood. 93: 306-314, 1999.
15. Chaudhary, P. M., Mechetner, E. B., and Roninson, I. B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood, 80: 2735-2739, 1992.
16. Luker, G. D., Fracasso, P. M., Dobkin, J., and Piwnica-Worms, D. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J. Nucl. Med., 38: 369-372, 1997.
17. Bakker, M., van der Graaf, W. T., Piers, D. A., Franssen, E. J., Groen, H. J., Smit, E. F., Kool, W., Hollema, H., Muller, E. A., and deVries, E. G. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours. Anticancer Res., 19: 2349-2353, 1999.
18. Chen, C. C., Meadows, B., Regis, J., Kalafsky, G., Fojo, T., Carrasquillo, J. A., and Bates, S. E. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin. Cancer Res., 3: 545-552, 1997.
19. Peck, R. A., Hewett, J., Harding, M. W., Wang, Y. M., Chaturvedi, P. R., Bhatnagar, A., Ziessman, H., Atkins, F., and Hawkins, M. J. Phase 1 and pharmacokinetic study of the novel MDRI and MRPI inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol., 19: 3130-3141, 2001.
20. Del Vecchio, S., Ciarmiello, A., Pace, L., Potena, M. I., Carriero, M. V., Mainolfi, C., Thomas, R., D'Aiuto, G., Tsuruo, T., and Salvatore, M. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J. Nucl. Med., 38: 1348-1351, 1997.
21. Sun, S. S., Hsieh, J. F., Tsai, S. C., Ho, Y. J., Lee, J. K., and Kao, C. H. Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results. Cancer Lett., 153: 95-100, 2000.
22. Sun, S. S., Hsieh, J. F., Tsai, S. C., Ho, Y. J., and Kao, C. H. Expression of drug resistance protein related to Tc-99m MIBI breast imaging. Anticancer Res., 20: 2021-2025. 2000.
23. Ciarmiello, A., Del Vecchio, S., Silvestro, P., Potena, M. I., Carriero, M. V., Thomas, R., Botti, G., D'Aiuto, G., and Salvatore, M. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J. Clin. Oncol., 16: 1677-1683, 1998.
24. Vecchio, S. D., Ciarmiello, A., Potena, M. I., Carriero, M. V., Mainolfi, C., Botti, G., Thomas, R., Cerra, M., D'Aiuto, G., Tsuruo, T., and Salvatore, M. In vivo detection of multidrug-resistant (MDRI) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients Eur. J. Nucl. Med., 24: 150-159, 1997.
25. Burak, Z., Ersoy, O., Moretti, J. L., Erinc, R., Ozcan, Z., Dirlik, A., Sabah, D., and Basdemir, G. The role of 99mTc-MIBI scintigraphy in the assessment of MDRI overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur. J. Nucl. Med., 28: 1341-1350, 2001.
26. Kao, C. H., Tsai, S. C., Wang, J. J., Ho, Y. J., Ho, S. T., and Changlai, S. P. Evaluation of chemotherapy response using technetium-99M-sestamibi scintigraphy in untreated adult malignant lymphomas and comparison with other prognosis factors: a preliminary report. Int. J. Cancer, 95: 228-231, 2001.
27. Kao, C. H., Tsai, S. C., Liu, T. J., Ho, Y. J., Wang, J. J., Ho, S. T., and ChangLai, S. P. P-Glycoprotein and multidrug resistance related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. Cancer Res., 61: 1412-1414, 2001.
28. Yamamoto, Y., Nishiyama, Y., Satoh, K., Takashima, H., Ohkawa, M., Fujita, J., Kishi, T., Matsuno, S., and Tanabe, M. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J. Nucl. Med., 39: 1626-1629, 1998.
29. Nishiyama, Y., Yamamoto, Y., Satoh, K., Ohkawa, M., Kameyama, K., Hayashi, E., Fujita, J., and Tanabe, M. Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. Clin. Nucl. Med., 25: 364-369, 2000.
30. Komori, T., Narabayashi, I., Matsui, R., Sueyoshi, K., Aratani, T., and Utsunomiya, K. Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer-preliminary report. Ann. Nucl. Med., 14: 415-420, 2000.
31. Kabasakal, L., Halac, M., Nisli, C., Oguz, O., Onsel, C., Civi, G., and Uslu, I. The effect of P-glycoprotein function inhibition with cyclosporine A on the biodistribution of Tc-99m sestamibi. Clin. Nucl. Med., 25: 20-23, 2000.
32. Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., and Pastan, I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA, 84: 265-269, 1987.
33. Hendrikse, N. H., Franssen, E. J., van der Graaf, W. T., Meijer, C., Piers, D. A., Vaalburg, W., and deVries, E. G. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br. J. Cancer, 77: 353-358, 1998.
34. Utsunomiya, K., Ballinger, J. R., Piquette-Miller, M., Rauth, A. M., Tang, W., Su, Z. F., and Ichise, M. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur. J. Nucl. Med., 27: 1786-1792, 2000.
35. Stewart, A., Steiner, J., Mellows, G., Laguda, B., Norris, D., and Bevan, P. Phase 1 trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin. Cancer Res., 6: 4186-4191, 2000.